Set up in 1981 in Hyderabad company is an R&D focused pharma company with 5 manufacturing facilities. It has > 3000 employees. Natco is into finished dosage formulations and API. It also does job works, pharmacy and others.
Natco is known for challenging patents in India and in 2012 became the 1st company to win a compulsory license from Bayer for its patent protected anti-cancer drug Nexavar.
Oncology accounts for a major part of company’s domestic formulations revenues. Post recent launch of Hep C drugs in India (license from Gilead to manufacture and sell the Hep C in over 100 countries) the revenues have grown strongly and expected to grow further
On the exports Natco has limited presence in US US. Export to US today is just 10% of sales. Natco partners with globally pharma companies to address US market.
Exports ex-US (EU, Brazil, Venezuela and RoW, with presence in over 40 countries) accounts for 15% of sales and mainly includes .
60% of Natco’s ANDAs are backward integrated. Natco has a portfolio of 38 niche ANDA filings in the US including 16 Para IV filings and 31 USDMFs filings
- Copaxone 20/40 mg US$4700mn
- Gleevec US$2500mn
- Gilenya US$1652mn
- Tamiflu US$667mn
- Treanda US$713mn
- Entocort US$519mn
- Nuvugil US$473mn
- Vidaza US$248mn
- Jevtana US$133mn
- Fosrenol US$120mn
- Tykerb US$79mn
- Revlimid US$3500mn
- Tracleer US$42mn
- Nexavar US$63mn
- Like any pharma company prone to a warning Letter or import alert from USFDA etc
- Delay in approvals of key products. For eg copaxone 20mg has been inordinately delayed.
Mr. Rajeev Nannapaneni and Mr. V. C. Nannapaneni
Other big investors
- PE CX Securities: 3.44%
- PE Hypnos Fund: 1.15%
- Dilip Shanghvi: 3.3%